Tag: PSMA
-
Lu-177 PNT2002 Added to SBRT Delays Prostate Cancer Progression
New approach combines Lu-177 PNT2002 with SBRT In a pioneering study presented at the American Society for Radiation Oncology (ASTRO) meeting, researchers explored whether adding lutetium-177 (Lu-177) PNT2002 to stereotactic body radiation therapy (SBRT) could improve outcomes for men with oligometastatic, or limited, prostate cancer. The strategy targets occult micrometastases that often drive progression after…
-
Radiopharmaceutical Therapy Boosts Radiation, Slows Prostate Cancer
What the LUNAR trial tested SAN FRANCISCO, September 28, 2025 — A new phase II clinical trial, called LUNAR, shows that adding a radiopharmaceutical drug before high-precision radiation therapy can help people with a limited number of metastatic lesions from recurrent prostate cancer live longer without disease progression. In this randomized study, patients received either…
-
Radiopharmaceutical Therapy Boosts Radiation to Slow Prostate Cancer
New Findings from the LUNAR Trial A landmark phase II study, known as the LUNAR trial, reports that people with recurrent prostate cancer and a limited number of metastases lived significantly longer without disease progression when a radiopharmaceutical drug was given before targeted radiation therapy, compared with high-precision radiation alone. The randomized study evaluated whether…
-
Radiopharmaceutical Therapy Boosts Radiation in Prostate Cancer
LUNAR Trial: Combining Radiopharmaceutical Therapy with SBRT A phase II study known as the LUNAR trial investigated whether adding a PSMA-targeted radiopharmaceutical before high-precision radiation could improve outcomes for men with oligometastatic, hormone-sensitive recurrent prostate cancer. In this randomized study, 92 participants with one to five distant lesions visible on PSMA PET/CT were assigned to…